Metabolic and neuroprotective effects of dapagliflozin and liraglutide in diabetic mice

IDF Diabetes Atlas estimates of 2014 global health expenditures on diabetes

(2016) Joao da Rocha Fernandes et al.   DIABETES RESEARCH AND CLINICAL PRACTICE

Modulation of GLP-1 signaling as a novel therapeutic approach in the treatment of Alzheimer’s disease pathology

(2016) Antonella Tramutola et al.   Expert Review of Neurotherapeutics

Glucose-Dependent Insulinotropic Peptide Stimulates Glucagon-Like Peptide 1 Production by Pancreatic Islets via Interleukin 6, Produced by α Cells

(2016) Katharina Timper et al.   GASTROENTEROLOGY

Beneficial metabolic actions of a stable GIP agonist following pre-treatment with a SGLT2 inhibitor in high fat fed diabetic mice

(2016) P.J.B. Millar et al.   MOLECULAR AND CELLULAR ENDOCRINOLOGY

Alzheimer's disease: Is this a brain specific diabetic condition?

(2016) Vanita Rani et al.   PHYSIOLOGY & BEHAVIOR

Modulation of GLP-1 signaling as a novel therapeutic approach in the treatment of Alzheimer’s disease pathology

(2016) Antonella Tramutola et al.   Expert Review of Neurotherapeutics

Future glucose-lowering drugs for type 2 diabetes

(2016) Clifford J Bailey et al.   Lancet Diabetes & Endocrinology

Dapagliflozin: A new sodium-glucose cotransporter 2 inhibitor for treatment of type 2 diabetes

(2015) E. M. Vivian   AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY

Durability and tolerability of dapagliflozin over 52 weeks as add-on to metformin and sulphonylurea in type 2 diabetes

(2015) S. Matthaei et al.   DIABETES OBESITY & METABOLISM

Sitagliptin, a dipeptidyl peptidase-4 inhibitor, improves recognition memory, oxidative stress and hippocampal neurogenesis and upregulates key genes involved in cognitive decline

(2015) V. A. Gault et al.   DIABETES OBESITY & METABOLISM

Dapagliflozin Lowers Plasma Glucose Concentration and Improves β-Cell Function

(2015) Aurora Merovci et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Incretin actions and consequences of incretin-based therapies: lessons from complementary animal models

(2015) Simone Renner et al.   JOURNAL OF PATHOLOGY

Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion

(2015) Caroline Bonner et al.   NATURE MEDICINE

Pathophysiology of type 1 and type 2 diabetes mellitus: a 90-year perspective

(2015) Francesco Zaccardi et al.   POSTGRADUATE MEDICAL JOURNAL

Potentials of incretin-based therapies in dementia and stroke in type 2 diabetes mellitus

(2015) Onno N Groeneveld et al.   Journal of Diabetes Investigation

Metabolic effects of SGLT-2 inhibitors beyond increased glucosuria: A review of the clinical evidence

(2014) A.J. Scheen et al.   DIABETES & METABOLISM

Positive effects of GLP-1 receptor activation with liraglutide on pancreatic islet morphology and metabolic control in C57BL/KsJdb/dbmice with degenerative diabetes

(2014) Rachel Charlotte Moffett et al.   DIABETES-METABOLISM RESEARCH AND REVIEWS

Efficacy and safety of dapagliflozin monotherapy in people with Type 2 diabetes: a randomized double-blind placebo-controlled 102-week trial

(2014) C. J. Bailey et al.   DIABETIC MEDICINE

Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients

(2014) Ele Ferrannini et al.   JOURNAL OF CLINICAL INVESTIGATION

Lixisenatide improves recognition memory and exerts neuroprotective actions in high-fat fed mice

(2014) Rachael Lennox et al.   PEPTIDES

Incretin Receptor Null Mice Reveal Key Role of GLP-1 but Not GIP in Pancreatic Beta Cell Adaptation to Pregnancy

(2014) R. Charlotte Moffett et al.   PLoS One

Role of Endogenous GLP-1 and GIP in Beta Cell Compensatory Responses to Insulin Resistance and Cellular Stress

(2014) Srividya Vasu et al.   PLoS One

High fat diet feeding results in gender specific steatohepatitis and inflammasome activation

(2014) Michal Ganz   WORLD JOURNAL OF GASTROENTEROLOGY

A novel GIP-oxyntomodulin hybrid peptide acting through GIP, glucagon and GLP-1 receptors exhibits weight reducing and anti-diabetic properties

(2013) Vikas K. Bhat et al.   BIOCHEMICAL PHARMACOLOGY

Tofogliflozin, a novel sodium-glucose co-transporter 2 inhibitor, improves renal and pancreatic function indb/dbmice

(2013) T Nagata et al.   BRITISH JOURNAL OF PHARMACOLOGY

Effects of LX4211, a Dual SGLT1/SGLT2 Inhibitor, Plus Sitagliptin on Postprandial Active GLP-1 and Glycemic Control in Type 2 Diabetes

(2013) Brian Zambrowicz et al.   CLINICAL THERAPEUTICS

Changes in Insulin Sensitivity and Insulin Secretion with the Sodium Glucose Cotransporter 2 Inhibitor Dapagliflozin

(2013) Sunder Mudaliar et al.   Diabetes Technology & Therapeutics

High-fat feeding rapidly induces obesity and lipid derangements in C57BL/6N mice

(2013) Christine Podrini et al.   MAMMALIAN GENOME

Long-term liraglutide treatment is associated with increased insulin content and secretion in β-cells, and a loss of α-cells in ZDF rats

(2013) Tiffany Schwasinger-Schmidt et al.   PHARMACOLOGICAL RESEARCH

A Novel Retro-Inverso Peptide Inhibitor Reduces Amyloid Deposition, Oxidation and Inflammation and Stimulates Neurogenesis in the APPswe/PS1ΔE9 Mouse Model of Alzheimer’s Disease

(2013) Vadivel Parthsarathy et al.   PLoS One

Liraglutide improves hippocampal synaptic plasticity associated with increased expression of Mash1 in ob/ob mice

(2012) W D Porter et al.   INTERNATIONAL JOURNAL OF OBESITY

Effects of Dapagliflozin on Body Weight, Total Fat Mass, and Regional Adipose Tissue Distribution in Patients with Type 2 Diabetes Mellitus with Inadequate Glycemic Control on Metformin

(2012) Jan Bolinder et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Weight Loss Induced by Chronic Dapagliflozin Treatment Is Attenuated by Compensatory Hyperphagia in Diet-Induced Obese (DIO) Rats

(2012) James J. Devenny et al.   Obesity

The Diabetes Drug Liraglutide Prevents Degenerative Processes in a Mouse Model of Alzheimer's Disease

(2011) P. L. McClean et al.   JOURNAL OF NEUROSCIENCE

Interleukin-6 enhances insulin secretion by increasing glucagon-like peptide-1 secretion from L cells and alpha cells

(2011) Helga Ellingsgaard et al.   NATURE MEDICINE

The novel sodium glucose transporter 2 inhibitor dapagliflozin sustains pancreatic function and preserves islet morphology in obese, diabetic rats

(2010) F. R. Macdonald et al.   DIABETES OBESITY & METABOLISM

Actions of exendin-4 therapy on cognitive function and hippocampal synaptic plasticity in mice fed a high-fat diet

(2010) V A Gault et al.   INTERNATIONAL JOURNAL OF OBESITY

Impairment of synaptic plasticity and memory formation in GLP-1 receptor KO mice: Interaction between type 2 diabetes and Alzheimer's disease

(2009) Talib Abbas et al.   BEHAVIOURAL BRAIN RESEARCH

Renal sodium–glucose transport: role in diabetes mellitus and potential clinical implications

(2009) George L. Bakris et al.   KIDNEY INTERNATIONAL

Dapagliflozin, a Selective SGLT2 Inhibitor, Improves Glucose Homeostasis in Normal and Diabetic Rats

(2008) S. Han et al.   DIABETES

Diet-induced insulin resistance impairs hippocampal synaptic plasticity and cognition in middle-aged rats

(2008) Alexis M. Stranahan et al.   HIPPOCAMPUS

Diabetes impairs hippocampal function through glucocorticoid-mediated effects on new and mature neurons

(2008) Alexis M Stranahan et al.   NATURE NEUROSCIENCE

Accelerated cognitive aging in diabetic rats is prevented by lowering corticosterone levels

(2008) Alexis M. Stranahan et al.   NEUROBIOLOGY OF LEARNING AND MEMORY

Interleukin-6 regulates pancreatic  -cell mass expansion

(2008) H. Ellingsgaard et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA